Pseudokinases-remnants of evolution or key allosteric regulators?

Current Opinion in Structural Biology

Volumn 20, Issue 6, 2010, Pages 772-781

  Zeqiraj, Elton ^a,b   van Aalten, Daan MF ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; INTEGRIN LINKED KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; KINASE SUPPRESSOR OF RAS 1; KINASE SUPPRESSOR OF RAS 2; PROTEIN KINASE; PSEUDOKINASE; RHOTROPY 2 PROTEIN; RHOTROPY 8 PROTEIN; STE20 RELATED ADAPTOR ALPHA PROTEIN; STE20 RELATED ADAPTOR BETA PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VACCINIA RELATED KINASE;

ALLOSTERISM; BIOLOGICAL ACTIVITY; CATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; ENZYME CONFORMATION; ENZYME DEGRADATION; ENZYME INACTIVATION; ENZYME REGULATION; ENZYME STRUCTURE; HUMAN; MOLECULAR EVOLUTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; AMINO ACID SEQUENCE; ANIMALS; EVOLUTION, MOLECULAR; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEOTIDES; PROTEIN KINASES; PSEUDOGENES;

EID: 78649642175     PISSN: 0959440X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.sbi.2010.10.001     Document Type: Review

References (73)

1. Knighton D.R., Zheng J.H., Teneyck L.F., Ashford V.A., Xuong N.H., Taylor S.S., Sowadski J.M. Crystal-structure of the catalytic subunit of cyclic adenosinemonophosphate dependent protein-kinase. Science 1991, 253:407-414.
2. Knighton D.R., Zheng J.H., Ten Eyck L.F., Xuong N.H., Taylor S.S., Sowadski J.M. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 1991, 253:414-420.
3. Hanks S.K., Quinn A.M., Hunter T. The protein-kinase family-conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52.
4. Taylor S.S., Radzio-Andzelm E. Three protein-kinase structures define a common motif. Structure 1994, 2:345-355.
5. Johnson L.N., Noble M.E.M., Owen D.J. Active and inactive protein kinases: structural basis for regulation. Cell 1996, 85:149-158.
6. Huse M., Kuriyan J. The conformational plasticity of protein kinases. Cell 2002, 109(3):275-282.
7. Nolen B., Taylor S., Ghosh G. Regulation of protein kinases; controlling activity through activation segment conformation. Mol Cell 2004, 15:661-675.
8. Scheeff E.D., Bourne P.E. Structural evolution of the protein kinase-like superfamily. PLoS Comp Biol 2005, 1:e49.
9. Kannan N., Taylor S.S., Zhai Y., Venter J.C., Manning G. Structural and functional diversity of the microbial kinome. PLoS Biol 2007, 5:e17.
10. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002, 298:1912-1934.
11. Finishing the euchromatic sequence of the human genome. Nature 2004, 431(7011):931-945. International Human Genome Sequencing, Consortium.
12. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M., FitzHugh W., et al. Initial sequencing and analysis of the human genome. Nature 2001, 409(6822):860-921.
13. Boudeau J., Miranda-Saavedra D., Barton G.J., Alessi D.R. Emerging roles of pseudokinases. Trends Cell Biol 2006, 16:443-452.
14. Kannan N., Taylor S.S. Rethinking pseudokinases. Cell 2008, 133(2):204-205.
15. Kornev A.P., Taylor S.S. Pseudokinases: functional insights gleaned from structure. Structure 2009, 17(1):5-7.
16. Rajakulendran T., Sicheri F. Allosteric protein kinase regulation by pseudokinases: insights from strad. Sci Signal 2010, 3(111):pe8.
17. Taylor S.S., Kornev A.P. Yet another äctive" pseudokinase, erb3. Proc Natl Acad Sci 2010, 107(18):8047-8048.
18. Richardson C., Alessi D.R. The regulation of salt transport and blood pressure by the WNK-SPAK/OSR1 signalling pathway. J Cell Sci 2008, 121(Pt 20):3293-3304.
19. Min X., Lee B.-H., Cobb M.H., Goldsmith E.J. Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure 2004, 12(7):1303-1311.
20. Mukherjee S.K., Sharma M., Urlaub H., Bourenkov G.P., Jahn R., Sudhof T.C., Wahl M.C. CASK Functions as a Mg2+-independent neurexin kinase. Cell 2008, 133(2):328-339.
21. Kawagoe T., Sato S., Matsushita K., Kato H., Matsui K., Kumagai Y., Saitoh T., Kawai T., Takeuchi O., Akira S. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nat Immunol 2008, 9(6):684-691.
22. Shi F., Telesco S.E., Liu Y., Radhakrishnan R., Lemmon M.A. Erbb3/her3 intracellular domain is competent to bind atp and catalyze autophosphorylation. Proc Natl Acad Sci 2010, 107(17):7692-7697.
23. Villa F., Capasso P., Tortorici M., Forneris F., de Marco A., Mattevi A., Musacchio A. Crystal structure of the catalytic domain of Haspin, an atypical kinase implicated in chromatin organization. Proc Natl Acad Sci USA 2009, 106(48):20204-20209.
24. Baas A.F., Boudeau J., Sapkota G.P., Smit L., Morrice N.A., Alessi D.R., Clevers H.C. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase. EMBO J 2003, 22:3062-3072.
25. Alessi D.R., Sakamoto K., Bayascas J.R. Lkb1-dependent signaling pathways. Annu Rev Biochem 2006, 75:137-163.
26. Boudeau J., Baas A.F., Deak M., Morrice N.A., Kieloch A., Schutowski M., Prescott A.R., Clevers H.C., Alessi D.R. MO25 isoforms interact with STRADα/β enhancing their ability to bind, activate and localise LKB1. EMBO J 2003, 22:5102-5114.
27. Zeqiraj E., Filippi B.M., Deak M., Alessi D.R., van Aalten D.M.F. Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science 2009, 326(5960):1707-1711.
28. Zeqiraj E., Filippi B.M., Goldie S., Navratilova I., Boudeau J., Deak M., Alessi D.R., van Aalten D.M.F. ATP and MO25α regulate the conformational state of the STRADα pseudokinase and activation of the LKB1 tumour suppressor. PLoS Biol 2009, 7(6):e1000126.
29. Taylor S.S., Yang J., Wu J., Haste N.M., Radzio-Andzelm E., Anand G. PKA: a portrait of protein kinase dynamics. Biochim Biophys Acta 2004, 1697(1-2):259-269.
30. Jeffrey P.D., Russo A.A., Polyak K., Gibbs E., Hurwitz J., Massagué J., Pavletich N.P. Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 1995, 376:313-320.
31. Dar A.C., Dever T.E., Sicheri F. Higher-order substrate recognition of eIF2alpha by the RNA-dependent protein kinase PKR. Cell 2005, 122(6):887-900.
32. Kim C., Xuong N.-H., Taylor S.S. Crystal structure of a complex between the catalytic and regulatory (RIalpha) subunits of PKA. Science 2005, 307(5710):690-696.
33. Komander D., Garg R., Wan P.T.C., Ridley A.J., Barford D. Mechanism of multi-site phosphorylation from a ROCK-I:RhoE complex structure. EMBO J 2008, 27(23):3175-3185.
34. Legate K.R., Montanez E., Kudlacek O., Fassler R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 2006, 7(1):20-31.
35. Wickstrom S.A., Lange A., Montanez E., Fassler R. The ILK/PINCH/parvin complex: the kinase is dead, long live the pseudokinase!. EMBO J 2010, 29(2):281-291.
36. Fukuda K., Gupta S., Chen K., Wu C., Qin J. The pseudoactive site of ilk is essential for its binding to α-parvin and localization to focal adhesions. Mol Cell 2009, 36(5):819-830.
37. Zhang X., Gureasko J., Shen K., Cole P.A., Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 2006, 125:1137-1149.
38. Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., Wemmer D.E., Zhang X., Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009, 137(7):1293-1307.
39. Jura N., Shan Y., Cao X., Shaw D.E., Kuriyan J. Structural analysis of the catalytically inactive kinase domain of the human egf receptor 3. Proc Natl Acad Sci 2009, 106(51):21608-21613.
40. Scheeff E.D., Eswaran J., Bunkoczi G., Knapp S., Manning G. Structure of the pseudokinase VRK3 reveals a degraded catalytic site, a highly conserved kinase fold, and a putative regulatory binding site. Structure 2009, 17(1):128-138.
41. Kornev A.P., Haste N.M., Taylor S.S., Eyck L.F.T. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci USA 2006, 103:17783-17788.
42. Kang T.-H., Kim K.-T. Negative regulation of ERK activity by VRK3-mediated activation of VHR phosphatase. Nat Cell Biol 2006, 8(8):863-869.
43. Kang T.-H., Kim K.-T. VRK3-mediated inactivation of ERK signaling in adult and embryonic rodent tissues. Biochim Biophys Acta 2008, 1783(1):49-58.
44. Labesse G., Gelin M., Bessin Y., Lebrun M., Papoin J., Cerdan R., Arold S.T., Dubremetz J.-F. ROP2 from Toxoplasma gondii: a virulence factor with a protein-kinase fold and no enzymatic activity. Structure 2009, 17(1):139-146.
45. Qiu W., Wernimont A., Tang K., Taylor S., Lunin V., Schapira M., Fentress S., Hui R., Sibley L.D. Novel structural and regulatory features of rhoptry secretory kinases in Toxoplasma gondii. EMBO J 2009, 28(7):969-979.
46. Lee K.P.K., Dey M., Neculai D., Cao C., Dever T.E., Sicheri F. Structure of the dual enzyme ire1 reveals the basis for catalysis and regulation in nonconventional RNA splicing. Cell 2008, 132:89-100.
47. Sharma R.K. Evolution of the membrane guanylate cyclase transduction system. Mol Cell Biochem 2002, 230(1-2):3-30.
48. Joubert S., Jossart C., McNicoll N., Lean A.D. Atrial natriuretic peptide-dependent photolabeling of a regulatory ATP-binding site on the natriuretic peptide receptor-A. FEBS J 2005, 272(21):5572-5583.
49. Bhandari R., Srinivasan N., Mahaboobi M., Ghanekar Y., Suguna K., Visweswariah S.S. Functional inactivation of the human guanylyl cyclase C receptor: modeling and mutation of the protein kinase-like domain. Biochemistry 2001, 40(31):9196-9206.
50. Jaleel M., Saha S., Shenoy A.R., Visweswariah S.S. The kinase homology domain of receptor guanylyl cyclase C: ATP binding and identification of an adenine nucleotide sensitive site. Biochemistry 2006, 45(6):1888-1898.
51. Kolch W. Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 2005, 6(11):827-837.
52. McKay M.M., Ritt D.A., Morrison D.K. Signaling dynamics of the KSR1 scaffold complex. Proc Natl Acad Sci USA 2009, 106(27):11022-11027.
53. Dougherty M.K., Ritt D.A., Zhou M., Specht S.I., Monson D.M., Veenstra T.D., Morrison D.K. KSR2 is a calcineurin substrate that promotes ERK cascade activation in response to calcium signals. Mol Cell 2009, 34(6):652-662.
54. Elion E.A. The Ste5p scaffold. J Cell Sci 2001, 114(Pt 22):3967-3978.
55. Bhattacharyya R.P., Remenyi A., Good M.C., Bashor C.J., Falick A.M., Lim W.A. The Ste5 scaffold allosterically modulates signaling output of the yeast mating pathway. Science 2006, 311(5762):822-826.
56. Good M., Tang G., Singleton J., Remenyi A., Lim W.A. The Ste5 scaffold directs mating signaling by catalytically unlocking the Fus3 MAP kinase for activation. Cell 2009, 136(6):1085-1097.
57. Morrison D.K., Davis R.J. Regulation of MAP kinase signaling modules by scaffold proteins in mammals. Annu Rev Cell Dev Biol 2003, 19(NIL):91-118.
58. Rajakulendran T., Sahmi M., Lefrançois M., Sicheri F., Therrien M. A dimerization-dependent mechanism drives raf catalytic activation. Nature 2009, 461(7263):542-545.
59. Saharinen P., Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 2002, 277(49):47954-47963.
60. Saharinen P., Vihinen M., Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 2003, 14(4):1448-1459.
61. Baxter E.J., Scott L.M., Campbell P.J., East C., Fourouclas N., Swanton S., Vassiliou G.S., Bench A.J., Boyd E.M., Curtin N., et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005, 365(9464):1054-1061.
62. James C., Ugo V., Couedic J.-P.L., Staerk J., Delhommeau F., Lacout C., Garcon L., Raslova H., Berger R., Bennaceur-Griscelli A., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005, 434(7037):1144-1148.
63. Levine R.L., Wadleigh M., Cools J., Ebert B.L., Wernig G., Huntly B.J.P., Boggon T.J., Wlodarska I., Clark J.J., Moore S., et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005, 7(4):387-397.
64. Malinge S., Ben-Abdelali R., Settegrana C., Radford-Weiss I., Debre M., Beldjord K., Macintyre E.A., Villeval J.-L., Vainchenker W., Berger R., et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood 2007, 109(5):2202-2204.
65. Bercovich D., Ganmore I., Scott L.M., Wainreb G., Birger Y., Elimelech A., Shochat C., Cazzaniga G., Biondi A., Basso G., et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 2008, 372(9648):1484-1492.
66. Kearney L., Castro D.G.D., Yeung J., Procter J., Horsley S.W., Eguchi-Ishimae M., Bateman C.M., Anderson K., Chaplin T., Young B.D., et al. Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 2009, 113(3):646-648.
67. Moorhead G.B.G., Wever V.D., Templeton G., Kerk D. Evolution of protein phosphatases in plants and animals. Biochem J 2009, 417(2):401-409.
68. Conner S.H., Kular G., Peggie M., Shepherd S., Schuttelkopf A.W., Cohen P., Aalten D.M.F.V. TAK1-binding protein 1 is a pseudophosphatase. Biochem J 2006, 399(3):427-434.
69. Barr A.J., Ugochukwu E., Lee W.H., King O.N.F., Filippakopoulos P., Alfano I., Savitsky P., Burgess-Brown N.A., Muller S., Knapp S. Large-scale structural analysis of the classical human protein tyrosine phosphatome. Cell 2009, 136(2):352-363.
70. Tonks N.K. Pseudophosphatases: grab and hold on. Cell 2009, 139(3):464-465.
71. Hurley J.H., Lee S., Prag G. Ubiquitin-binding domains. Biochem J 2006, 399(3):361-372.
72. Nijman S.M.B., Luna-Vargas M.P.A., Velds A., Brummelkamp T.R., Dirac A.M.G., Sixma T.K., Bernards R. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005, 123(5):773-786.
73. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6):855-867.